OncoMatch/Clinical Trials/NCT06608342

Autologous Hematopoietic Stem Cell Transplantation Combined With CD19-CART Treatment of Adult High-risk Acute Lymphoblastic Leukemia

Is NCT06608342 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Autologous hematopoietic stem cell transplantation combined with CD19-CART for acute lymphoblastic leukemia all.

Phase 2RecruitingInstitute of Hematology & Blood Diseases Hospital, ChinaNCT06608342Data as of May 2026

Treatment: Autologous hematopoietic stem cell transplantation combined with CD19-CART — To observe the efficacy and side effects of autologous hematopoietic stem cell transplantation combined with CD19-CART for adult acute lymphoblastic leukemia, and to evaluate the safety and efficacy of this regimen in the treatment of acute lymphoblastic leukemia.

Check if I qualify

Extracted eligibility criteria

Cancer type

Acute Lymphoblastic Leukemia

Biomarker criteria

Required: CD19 expression

Prior therapy

Must have received: induction chemotherapy

Complete remission was achieved after induction chemotherapy

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify